|
|
News Breaks
|
September 8, 2010
|
| 16:17 EDT |  | QCOR |
| theflyonthewall.com: | Questcor says FDA needs additional time for Acthar Gel review | | Questcor Pharmaceuticals announced that the FDA has informed Questcor that the FDA will require additional time beyond the current action date of September 11 to complete its review of Questcor's supplemental new drug application for H.P. Acthar Gel in the treatment of infantile spasms. In conjunction with the FDA's review of this sNDA, Questcor and the FDA have been updating and modernizing the product label for Acthar, which has not been modified since 1978, when multiple sclerosis was added to the label. This step of the review process is now complete. Questcor has been notified that the FDA needs some additional time to finalize the wording on the label, review the proposed medication guide, and define post-approval commitments, if any, for the IS indication. :theflyonthewall.com |
|
|
News For QCOR From The Last 14 Days Check below for free stories on QCOR the last two weeks.
There are 5 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 10, 2012
|
| 09:28 EDT |  | QCOR |
|
|
February 3, 2012
|
| 10:19 EDT | | QCOR |
| | 09:19 EDT |  | QCOR |
| | 09:17 EDT | | QCOR |
| theflyonthewall.com: | Questcor sees Q4 operating income 'approximately' $41M-$43M vs. $29.3M year-ago |
 Subscribe for More Information :theflyonthewall.com |
|
|
January 30, 2012
|
| 07:37 EDT | | QCOR |
| theflyonthewall.com: | Questcor overhang removed, says Oppenheimer | | After an investor blog published its second article which was critical of Questcor, Oppenheimer believes the article has little credibility. while the blog's objectiveness is questionable. The firm maintains an Outperform rating on the stock. :theflyonthewall.com |
|
|
|
|
|
